Two years with GIOIA ‘Effects of gliflozins and gliptins on markers of cardiovascular damage in type 2 diabetes’: A prospective, multicentre, quasi‐experimental study on sodium‐glucose cotransporter 2 and dipeptidyl peptidase‐4 inhibitors in diabetes clinical practice
Authors' conclusion
In a real-world setting, both SGLT-2i and DPP-4i improve glycaemic control persisting after 2 years of treatment, with a robust effect on both CIMT and albuminuria regression for SGLT-2i as compared with DPP-4i in the propensity score matching.
Study context
- Population
- Patients with T2D initiating SGLT-2i or DPP-4i for inadequate glycaemic control (HbA1c >7%), March 2018–March 2021, Italian clinical practice155 per group after PS matching
- Participants
- 1,150 patients
- Exposure
- SGLT-2i vs DPP-4i
- SGLT-2in = 580
- DPP-4in = 570reference
- Outcome
- Changes in markers of organ damage (CIMT, albuminuria, myocardial function) and HbA1c
- Follow-up
- Baseline to year 2
Methodological detailsmulticentre, propensity score matching
- Multicentre
- Propensity score matching
Main finding
As reported in the abstract
CIMT, albuminuria, myocardial function and HbA1c (propensity score matched) · 2 years
Significant similar HbA1c reduction in both groups
−0.8%
More SGLT-2i patients had regression of carotid intima-media thickness (CIMT) and albuminuria
22% and 10%, respectively
More DPP-4i patients had progression of CIMT and albuminuria
23% and 28%, respectively
LVEF improved slightly on SGLT-2i only
3%
p = .043
Observational data: associations, not effects.
Original publication
Two years with GIOIA ‘Effects of gliflozins and gliptins on markers of cardiovascular damage in type 2 diabetes’: A prospective, multicentre, quasi‐experimental study on sodium‐glucose cotransporter 2 and dipeptidyl peptidase‐4 inhibitors in diabetes clinical practice. Diabetes Obes Metab. Published 17 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →